We are live on ! Find out more
B

Bellecapital Portfolio holdings

AUM $625M Turnover 41.45%
1-Year Est. Return 39.69%
This Fund
S&P 500
This Quarter Est. Return
+7.59%
1 Year Est. Return
+39.69%
3 Year Est. Return
+127.77%
5 Year Est. Return
+155.51%
10 Year Est. Return
+530.96%
AUM
$153M
AUM Growth
+$14M
Cap. Flow
+$5.17M
Cap. Flow %
3.39%
Top 10 Hldgs %
43.38%
Holding
102
New
13
Increased
21
Reduced
25
Closed
17
Avg Time Held
1.5 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
2.1 years

Top Buys

Rank Stock Value
1
KO icon
Coca-Cola
KO
+$6.13M
2
CRM icon
Salesforce
CRM
+$2.21M
3
MOMO icon
Hello Group
MOMO
+$2.19M
4
IVV icon
iShares Core S&P 500 ETF
IVV
+$966K
5
WB icon
Weibo
WB
+$853K

Sector Composition

Rank Sector Weight
1 Miscellaneous 25.09%
2 Consumer Discretionary 14.83%
3 Technology 14.32%
4 Healthcare 13.09%
5 Communication Services 11.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
LFC
101
DELISTED
China Life Insurance Company Ltd.
LFC
– –
-22,730
Closed -$290K –
BPY
102
DELISTED
Brookfield Property Partners L.P. Limited Partnership Units
BPY
– –
-15,850
Closed -$301K –

Similar funds

Bellecapital's Q3 2018 Portfolio in Review

As of Q3 2018, Bellecapital held 102 positions worth $153M, up 10% from $138M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Bellecapital deployed $5.17M of net new capital in Q3 2018, opening 13 new positions and adding to 21 existing holdings. Its largest new stake was Salesforce: 14,895 shares worth $2.37M.

By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, down from 27% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was iShares Biotechnology ETF, an estimated $833K trimmed.

  • Bellecapital's largest Q3 2018 buy was Salesforce: 14,895 shares worth $2.37M.
  • Bellecapital added most to Coca-Cola in Q3 2018, an estimated $6.13M increase.
  • Bellecapital's biggest Q3 2018 reduction was iShares Biotechnology ETF, cutting an estimated $833K.
  • Bellecapital fully exited SLB Ltd in Q3 2018, selling an estimated $3.48M.
  • Bellecapital's ten largest holdings make up 43% of its $153M portfolio in Q3 2018.
  • Bellecapital opened 13 new positions and closed 17 in Q3 2018.
  • Bellecapital's portfolio value rose 10% quarter-over-quarter to $153M.

Based on Bellecapital's 13F filing for Q3 2018, filed 12 Oct 2018.